MedTrace Logo

Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia

NCT03210532 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2018-02-01

No results posted yet for this study

Summary

A Multicenter, Randomized, Double-blinded, Double-dummy, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Treatment with DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients with Hypertension and Dyslipidemia

Conditions

Interventions

DRUG

Telmisartan + Amlodipine + Rosuvastatin

Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo

DRUG

Telmisartan + Amlodipine

Telmisartan + Amlodipine + Rosuvastatin placebo + Telmisartan placebo

DRUG

Telmisartan + Rosuvastatin

Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo

Sponsors & Collaborators

  • Daewon Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-07
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03210532 on ClinicalTrials.gov